Article
Leukemogenic potency of the novel FLT3-N676K mutant.
Annals of hematology - 1 Apr 2016
Huang Kezhi, Yang Min, Pan Zengkai, Heidel Florian H, Scherr Michaela, Eder Matthias, Fischer Thomas, Büsche Guntram, Welte Karl, von Neuhoff Nils, Ganser Arnold, Li Zhixiong
Abstract excerpt
The novel FMS-like tyrosine kinase 3 (FLT3)-N676K point mutation within the FLT3 kinase domain-1 was recently identified in 6 % of de novo acute myeloid leukemia (AML) patients with inv(16). Because FLT3-N676K was encountered almost exclusively in inv(16) AML, we investigated the transforming potential of FLT3-N676K, the cooperation between FLT3-N676K and core binding factor ß-smooth muscle myosin heavy chain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.